Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Vistin Pharma ASA ( (DE:VP4) ) just unveiled an update.
Vistin Pharma reported first-quarter 2026 revenue of NOK 112 million and EBITDA of NOK 27 million, with sales and earnings slightly above last year when adjusted for currency. Sales volumes rose 9% to 1,520 metric tons, but stronger NOK and lower global metformin prices weighed on topline growth, while net profit was stable at NOK 21.5 million and net cash stood at NOK 6 million.
Management highlighted that the company is currently shielded from potential supply chain issues stemming from the Middle East Hormuz situation due to earlier stockpiling of critical inputs. The board has proposed an ordinary dividend of up to NOK 1.50 per share, to be paid in two tranches, signalling confidence in cash generation and offering an attractive payout to shareholders despite expected increases in freight and raw material costs that could lift metformin prices globally.
More about Vistin Pharma ASA
Vistin Pharma ASA is a Norwegian pharmaceutical manufacturer focused on producing metformin, a key drug for treating type 2 diabetes, for the global market. The company has invested in increased production capacity and maintains significant safety stocks of critical raw materials to support reliable supply and mitigate logistics disruptions.
Average Trading Volume: 13,856
Current Market Cap: NOK1.02B
See more data about VP4 stock on TipRanks’ Stock Analysis page.